Although there are currently no ongoing clinical trials concerning the PKD family in metabolic disorders, targeting PKD isoforms may still represent a promising strategy for the treatment of obesity and diabetes. The gene discussed is PRKD1; the disease is obesity due to melanocortin 4 receptor deficiency.